Characterizing antibodies targeting antisense oligonucleotide modifications
Researchers validated panels of antibodies targeting clinically relevant nucleic acid modifications to visualize antisense oligonucleotides in both in vitro and in vivo studies. The tools enable detection of modified nucleic acids irrespective of sequence, facilitating multiple clinical and pre-clinical workflows.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·TypeExperimental study·DateJul 31, 2025